Parallax Volatility Advisers’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Parallax Volatility Advisers’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-30,000	Closed	-$521K	–	2346
2023 Q3	$521K	Sell	30,000 -35,000	-54%	-$590K	﹤0.01%	1579
2023 Q2	$915K	Buy	65,000 +30,000	+86%	+$402K	﹤0.01%	1435
2023 Q1	$377K	Buy	+35,000	New	+$461K	﹤0.01%	1818
2021 Q3	–	Sell	-22,600	Closed	-$315K	–	3221
2021 Q2	$315K	Hold	22,600	–	–	﹤0.01%	2335
2021 Q1	$418K	Buy	+22,600	New	+$462K	﹤0.01%	2447

Other funds holding KNSA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return

Parallax Volatility Advisers's KNSA Position: Q2 2023 in Review

Parallax Volatility Advisers sold out of Kiniksa Pharmaceuticals (KNSA) in Q2 2023, closing a stake of 7,978 shares — an estimated $107K sold.

Parallax Volatility Advisers first reported a position in KNSA in Q1 2021 and held it in 3 quarters. The position peaked at $231K in Q2 2021. 127 funds tracked by Wall St. Rank hold KNSA as of Q2 2023.

Parallax Volatility Advisers reported no remaining Kiniksa Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Parallax Volatility Advisers sold 7,978 Kiniksa Pharmaceuticals shares in Q2 2023, an estimated $107K.
Parallax Volatility Advisers first reported a position in Kiniksa Pharmaceuticals in Q1 2021 and held it in 3 quarters.
Parallax Volatility Advisers's Kiniksa Pharmaceuticals position peaked at $231K in Q2 2021.
127 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2023.

Based on Parallax Volatility Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.